18.2  16.47 (952.02%)		10-04 16:00
Open: 1.68 High: 18.2 Volume: 437,523		Pre. Close: 1.73 Low: 1.68 Market Cap: 61(M)

Short term
Mid term
Targets	6-month :	21.25	1-year :	24.82
Resists	First :	18.2	Second :	21.25
Pivot price	15.65
Supports	First :	7.99	Second :	1.67
MAs	MA(5) :	17.21	MA(20) :	15.23
	MA(100) :	15.52	MA(250) :	0
MACD	MACD :	0.7	Signal :	0.3
%K %D	K(14,3) :	91.9	D(3) :	89.7
RSI	RSI(14): 69.8
52-week	High :	81.5	Low :	1.67

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ RPHM ] has closed below upper band by 4.2%. Bollinger Bands are 114.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	18.22 - 18.29	18.29 - 18.34
Low:	1.66 - 1.67	1.67 - 1.68
Close:	18.07 - 18.2	18.2 - 18.31

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Fri, 11 Oct 2024
Cormorant Asset Management's Strategic Acquisition of Reneo Pharmaceuticals Shares - Yahoo Finance

Wed, 02 Oct 2024
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure - GlobeNewswire

Tue, 14 May 2024
These Are the Most Heavily Shorted Stocks Heating Up the Market - 24/7 Wall St.

Mon, 13 May 2024
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Reneo Pharmaceuticals, Inc. - RPHM - GuruFocus

Mon, 13 May 2024
Reneo Pharmaceuticals and OnKure Announce Proposed Merger - GlobeNewswire

Thu, 14 Dec 2023
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	3 (M)
Shares Float	3 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	340 (K)
Shares Short P.Month	326 (K)

EPS	-16.8
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	23
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-33.8 %
Return on Equity (ttm)	-54 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-18.29
Qtrly Earnings Growth	0 %
Operating Cash Flow	-66 (M)
Levered Free Cash Flow	-43 (M)

PE Ratio	-1.09
PEG Ratio	0
Price to Book value	0.79
Price to Sales	0
Price to Cash Flow	-0.92

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.